13F-HR filed by Sarissa Capital Management LP
Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 9 holding rows worth $648,896,720.
- Accession
- 0000899140-24-000250
- Filer
- CIK 1577524
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 9 entries on the cover page, a total value of $648,896,720 stated on the cover page (in dollars after the unit check, H1), rows summing to $648,896,720 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC | 46333X108 | COMMON STOCK | 16,390,000 | $187,501,600 | dollars as filed | |
| BIOGEN INC COM | 09062X103 | Stock | 643,000 | $166,389,110 | dollars as filed | |
| INNOVIVA INC | 45781M101 | COM | 7,277,000 | $116,723,080 | dollars as filed | |
| Gilead Sciences,Inc. | 375558103 | COM | 1,075,400 | $87,118,154 | dollars as filed | |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | COM | 470,000 | $61,927,200 | dollars as filed | |
| AMARIN CORP PLC | 023111206 | SPONS ADR NEW | 24,850,623 | $21,620,042 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 1,000,000 | $5,990,000 | dollars as filed | |
| VOR BIOPHARMA INC | 929033108 | COM | 618,000 | $1,390,500 | dollars as filed | |
| REGULUS THERAPEUTICS INC | 75915K309 | COM | 185,183 | $237,034 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000899140-24-000250 | this filing | 2024-02-14 | acceptance time not in the bulk data set |